267 related articles for article (PubMed ID: 28482067)
21. Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system.
Yuzawa S; Nishihara H; Yamaguchi S; Mohri H; Wang L; Kimura T; Tsuda M; Tanino M; Kobayashi H; Terasaka S; Houkin K; Sato N; Tanaka S
Mod Pathol; 2016 Jul; 29(7):708-16. PubMed ID: 27102344
[TBL] [Abstract][Full Text] [Related]
22. Clinical Characteristics and Magnetic Resonance Imaging-Based Prediction of the KLF4
von Spreckelsen N; Waldt N; Timmer M; Goertz L; Reinecke D; Laukamp K; Pennig L; Grau S; Deckert M; Kirches E; Stavrinou P; Mawrin C; Goldbrunner R
World Neurosurg; 2021 Oct; 154():e665-e670. PubMed ID: 34343686
[TBL] [Abstract][Full Text] [Related]
23. AKT1
John P; Waldt N; Liebich J; Kesseler C; Schnabel S; Angenstein F; Sandalcioglu IE; Scherlach C; Sahm F; Kirches E; Mawrin C
Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12780. PubMed ID: 34837233
[TBL] [Abstract][Full Text] [Related]
24. A new amplicon-based gene panel for next generation sequencing characterization of meningiomas.
Mawrin C; Koch R; Waldt N; Sandalcioglu IE; Braunsdorf WEK; Warnke JP; Goehre F; Meisel HJ; Ewald C; Neyazi S; Schüller U; Kirches E
Brain Pathol; 2022 Mar; 32(2):e13046. PubMed ID: 35213080
[TBL] [Abstract][Full Text] [Related]
25. Cucurbitacin I blocks cerebrospinal fluid and platelet derived growth factor-BB stimulation of leptomeningeal and meningioma DNA synthesis.
Johnson MD; O'Connell MJ; Walter K
BMC Complement Altern Med; 2013 Nov; 13():303. PubMed ID: 24188277
[TBL] [Abstract][Full Text] [Related]
26. Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling.
Mei Y; Du Z; Hu C; Greenwald NF; Abedalthagafi M; Agar NYR; Dunn GP; Bi WL; Santagata S; Dunn IF
Cell Commun Signal; 2017 Sep; 15(1):34. PubMed ID: 28923059
[TBL] [Abstract][Full Text] [Related]
27. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
Beauchamp RL; Erdin S; Witt L; Jordan JT; Plotkin SR; Gusella JF; Ramesh V
J Biol Chem; 2021; 296():100157. PubMed ID: 33273014
[TBL] [Abstract][Full Text] [Related]
28. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
29. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
Brastianos PK; Horowitz PM; Santagata S; Jones RT; McKenna A; Getz G; Ligon KL; Palescandolo E; Van Hummelen P; Ducar MD; Raza A; Sunkavalli A; Macconaill LE; Stemmer-Rachamimov AO; Louis DN; Hahn WC; Dunn IF; Beroukhim R
Nat Genet; 2013 Mar; 45(3):285-9. PubMed ID: 23334667
[TBL] [Abstract][Full Text] [Related]
30. NF2 status of meningiomas is associated with tumour localization and histology.
Kros J; de Greve K; van Tilborg A; Hop W; Pieterman H; Avezaat C; Lekanne Dit Deprez R; Zwarthoff E
J Pathol; 2001 Jul; 194(3):367-72. PubMed ID: 11439370
[TBL] [Abstract][Full Text] [Related]
31. High p-mTOR expression is associated with recurrence and shorter disease-free survival in atypical meningiomas.
Barresi V; Lionti S; La Rocca L; Caliri S; Caffo M
Neuropathology; 2019 Feb; 39(1):22-29. PubMed ID: 30511495
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological and molecular characteristics of pediatric meningiomas.
Battu S; Kumar A; Pathak P; Purkait S; Dhawan L; Sharma MC; Suri A; Singh M; Sarkar C; Suri V
Neuropathology; 2018 Feb; 38(1):22-33. PubMed ID: 28901666
[TBL] [Abstract][Full Text] [Related]
33. The spatial phenotype of genotypically distinct meningiomas demonstrate potential implications of the embryology of the meninges.
Fountain DM; Smith MJ; O'Leary C; Pathmanaban ON; Roncaroli F; Bobola N; King AT; Evans DG
Oncogene; 2021 Feb; 40(5):875-884. PubMed ID: 33262459
[TBL] [Abstract][Full Text] [Related]
34. Somatic AKT1 mutations cause meningiomas colocalizing with a characteristic pattern of cranial hyperostosis.
Keppler-Noreuil KM; Baker EH; Sapp JC; Lindhurst MJ; Biesecker LG
Am J Med Genet A; 2016 Oct; 170(10):2605-10. PubMed ID: 27550858
[TBL] [Abstract][Full Text] [Related]
35. Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker.
Parada CA; Osbun JW; Busald T; Karasozen Y; Kaur S; Shi M; Barber J; Adidharma W; Cimino PJ; Pan C; Gonzalez-Cuyar LF; Rostomily R; Born DE; Zhang J; Ferreira M
Clin Cancer Res; 2020 Jan; 26(1):193-205. PubMed ID: 31615938
[TBL] [Abstract][Full Text] [Related]
36. Loss of
Malgulwar PB; Kakkar A; Sharma MC; Ghosh R; Pathak P; Sarkar C; Suri V; Singh M; Kale SS; Faruq M
Neurol India; 2019; 67(6):1492-1497. PubMed ID: 31857543
[TBL] [Abstract][Full Text] [Related]
37. High-grade meningiomas: biology and implications.
Bi WL; Prabhu VC; Dunn IF
Neurosurg Focus; 2018 Apr; 44(4):E2. PubMed ID: 29606053
[TBL] [Abstract][Full Text] [Related]
38. Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas.
Peyre M; Feuvret L; Sanson M; Navarro S; Boch AL; Loiseau H; Kalamarides M
J Neurooncol; 2017 Jul; 133(3):633-639. PubMed ID: 28536991
[TBL] [Abstract][Full Text] [Related]
39. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
40. mTOR Signaling and Potential Therapeutic Targeting in Meningioma.
Pinker B; Barciszewska AM
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
